Current Clinical Trials
- DEP® docetaxel – Phase 2
-
DEP® cabazitaxel – Phase 1 / 2
-
DEP® irinotecan – Phase 1 / 2
DEP® docetaxel – Phase 2
Status: Recruiting patients
- Open-label, two-stage design
- Objectives are to establish anti-tumour activity (efficacy) and safety of DEP® docetaxel (at the Recommended phase 2 Dose (RP2D) of 60mg/m2)
- First stage to enrol ~20 patients with either lung or prostate cancer (the key approved indications for standard docetaxel (e.g. Taxotere®))
- Second stage to enrol a further 20 patients (tumour types based on results from the first stage)
- Also investigating the potential benefits of combining DEP® docetaxel with another anti-cancer agent, nintedanib (Vargatef®)
Download: DEP docetaxel positive phase 1 results; phase 2 commences (pdf, 363kb)
Download: DEP® docetaxel and gemcitabine combination trial commences (pdf 67kb)
DEP® cabazitaxel - Phase 1 / 2
Status: Recruiting patients
- Open-label, two-part study (phase 1: open label dose escalation & phase 2: dose expansion to establish efficacy)
- Objectives are to define the maximum tolerated dose (MTD) to establish safety and explore anti-tumour activity (efficacy) of DEP® cabazitaxel
- Planning to enrol approximately 35 patients across the phase 1 / 2 trial, with the trial being conducted at multiple sites including Guy’s Hospital London and University College London Hospital
Download: Starpharma to commence DEP cabazitaxel phase 1 / 2 trial (pdf, 147kb)
Download: DEP cabazitaxel progresses to phase 2 on positive results (pdf, 306kb)
DEP® irinotecan - Phase 1 / 2
Status: Recruiting patients
- Open-label, two-part study (phase 1: open label dose escalation & phase 2: dose expansion to establish efficacy)
- Objectives are to evaluate the safety, tolerability and pharmacokinetics of DEP® irinotecan to define a recommended phase 2 dose (RP2D), and to determine anti-tumour efficacy of the product in select tumour types
- Planning to enrol approximately ~40-45 patients across the phase 1 / 2 trial; initial trial sites include The Christie, Newcastle Freeman Hospital and The Royal Marsden
Download: Starpharma commences phase 1/2 DEP® irinotecan trial (pdf, 147kb)
Download: DEP® irinotecan phase 2 commences after positive phase 1 results (pdf file, 109kb)